Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
Jason Grebely, Gail V Matthews, Margaret Hellard, David Shaw, Ingrid van Beek, Kathy Petoumenos, Maryam Alavi, Barbara Yeung, Paul S Haber, Andrew R Lloyd, John M Kaldor, Gregory J Dore
Journal of Hepatology | ELSEVIER | Published : 2011
BACKGROUND & AIMS: Adherence to HCV therapy impacts sustained virological response (SVR) but there are limited data on adherence, particularly among injecting drug users (IDUs). We assessed 80/80 adherence (≥80% of PEG-IFN doses, ≥80% treatment), on-treatment adherence, and treatment completion in a study of treatment of recent HCV infection (ATAHC). METHODS: Participants with HCV received pegylated interferon (PEG-IFN) alfa-2a (180μg/week, n=74) and those with HCV/HIV received PEG-IFN alfa-2a with ribavirin (n=35), for a planned 24 weeks. Logistic regression analyses were used to identify predictors of PEG-IFN 80/80 adherence. RESULTS: A total of 109 out of 163 patients received treatment (..View full abstract
Awarded by National Institutes of Health
Awarded by NATIONAL INSTITUTE ON DRUG ABUSE
This study was funded by the National Institutes of Health grant RO1 DA 15999-01. The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Aging and is affiliated with the Faculty of Medicine, University of New South Wales. Roche Pharmaceuticals supplied financial support for pegylated IFN-alfa-2a/ribavirin. G.D., P.H. and At were supported by National Health and Medical Research Council Practitioner Research Fellowships. M.H. was supported by a National Health and Medical Research Council Career Development Award and a VicHealth Senior Research Fellowship. J.K. was supported by National Health and Medical Research Council Research Fellowship.